2,3-dihydro-1H-pyrrolizine-7-formamide derivative and application thereof

1. A compound of formula (II) or a pharmaceutically acceptable salt thereof,

wherein,

m is 1;

L is selected from

T 1 is selected from the group consisting of N and C (R 43 );

R 2 is selected from the group consisting of H and C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted by 1, 2, or 3 R b ;

R 3 is selected from the group consisting of Cl, F, Br, I, OH, NH 2 , C 1-6 alkyl, and C 1-3 alkoxy, wherein the C 1-6 alkyl and the C 1-3 alkoxy are optionally substituted by 1, 2, or 3 R c ;

R 41 , R 42 , R 43 , R 44 , and R 45 are each independently selected from the group consisting of H, Cl, F, Br, I, OH, NH 2 , CN, COOH, and C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted by 1, 2, or 3 R d ;

R 5 is selected from the group consisting of R 51 , C 3-10 cycloalkyl, and 3-6 membered heterocycloalkyl, wherein the C 3-10 cycloalkyl and the 3-6 membered heterocycloalkyl are optionally substituted by 1, 2, or 3 R 1 ;

R 51 is selected from the group consisting of C 1-7 alkyl and C 1-6 heteroalkyl, wherein the C 1-7 alkyl and the C 1-6 heteroalkyl are optionally substituted by 1, 2, or 3 R e ;

R 1 is each independently selected from the group consisting of H, Cl, F, Br, I, OH, NH 2 , CN, COOH, C 1-6 alkyl, —COO—C 1-6 alkyl, and —C 1-3 alkyl-COO—C 1-6 alkyl, wherein the C 1-6 alkyl, the —COO—C 1-6 alkyl, and the —C 1-3 alkyl-COO—C 1-6 alkyl are optionally substituted by 1, 2, or 3 R a ;

R a is each independently selected from the group consisting of Cl, F, Br, I, NH 2 , CN, COOH, C 1-3 alkyl, and C 1-3 alkoxy, wherein the C 1-3 is optionally substituted by 1, 2, or 3 R;

R b is each independently selected from the group consisting of Cl, F, Br, I, OH, NH 2 , CN, and COOH;

R e is each independently selected from the group consisting of Cl, F, Br, I, OH, NH 2 , CN, COOH, and C 1-3 alkyl, wherein the C 1-3 is optionally substituted by 1, 2, or 3 R;

R d is each independently selected from the group consisting of Cl, F, Br, I, OH, NH 2 , CN, and COOH;

R e is each independently selected from the group consisting of Cl, F, Br, I, OH, NH 2 , CN, and COOH;

R is each independently selected from the group consisting of Cl, F, Br, I, OH, NH 2 , CN, and COOH; and

the C 1-6 heteroalkyl and the 3-6 membered heterocycloalkyl each contain 1, 2, 3, or 4 heteroatoms or heteroatom groups independently selected from the group consisting of —NH—, —O—, —S—, and N.

2. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R a is selected from the group consisting of Cl, F, Br, I, NH 2 , CN, COOH, and —OCH 3 ; or R e is selected from the group consisting of Cl, F, Br, I, OH, NH 2 , CN, and COOH.

3. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is each independently selected from the group consisting of H, Cl, F, Br, I, OH, NH 2 , CN, COOH, C 1-3 alkyl, —COO—C 1-3 alkyl, and —C 1-3 alkyl-COO—C 1-3 alkyl, wherein the C 1-3 alkyl, the —COO—C 1-3 alkyl, and the —C 1-3 alkyl-COO—C 1-3 alkyl are optionally substituted by 1, 2, or 3 R a .

4. The compound or the pharmaceutically acceptable salt thereof according to claim 3 , wherein R 1 is each independently selected from the group consisting of H, Cl, F, Br, I, OH, NH 2 , CN, COOH, CH 3 , Et,

wherein the CH 3 , the Et,

and the

are optionally substituted by 1, 2, or 3 R a .

5. The compound or the pharmaceutically acceptable salt thereof according to claim 4 , wherein R 1 is each independently selected from the group consisting of H, Cl, F, Br, I, OH, NH 2 , CN, COOH, CH 3 , CF 3 , Et, —CH 2 —COOH, —CH 2 —OCH 3 , —(CH 2 ) 2 —COOH,

6. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is selected from the group consisting of H and C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted by 1, 2, or 3 R b .

7. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 3 is selected from the group consisting of Cl, F, Br, I, OH, NH 2 , and C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted by 1, 2, or 3 R c .

8. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 41 , R 42 , R 43 , R 44 , and R 45 are each independently selected from the group consisting of H, Cl, F, Br, I, OH, NH 2 , CN, and —COOH.

9. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 51 is selected from the group consisting of C 1-7 alkyl and C 1-3 heteroalkyl, wherein the C 1-7 alkyl and the C 1-3 heteroalkyl are optionally substituted by 1, 2, or 3 R e .

10. The compound or the pharmaceutically acceptable salt thereof according to claim 9 , wherein R 51 is selected from the group consisting of methyl, ethyl, propyl, isopropyl,

wherein the methyl, the ethyl, the propyl, the isopropyl, the

and the

are optionally substituted by 1, 2, or 3 R e .

11. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 5 is selected from the group consisting of R 51 , C 3-8 cycloalkyl, and 5-6 membered heterocycloalkyl, wherein the C 3-8 cycloalkyl and the 5-6 membered heterocycloalkyl are optionally substituted by 1, 2, or 3 R 1 .

12. The compound or the pharmaceutically acceptable salt thereof according to claim 11 , wherein R 5 is selected from the group consisting of R 51 , cyclohexyl, tetrahydropyranyl, piperidinyl and bicyclo[2.2.2]octyl, wherein the cyclohexyl, the tetrahydropyranyl, the piperidinyl, and the bicyclo[2.2.2]octyl are optionally substituted by 1, 2, or 3 R 1 .

13. The compound or the pharmaceutically acceptable salt thereof according to claim 12 , wherein R 5 is selected from the group consisting of R 51 ,

14. The compound or the pharmaceutically acceptable salt thereof according to claim 13 , wherein R 5 is selected from the group consisting of

15. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein structural unit

is selected from the group consisting of

16. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , selected from the group consisting of

wherein each of R 1 , R 2 , R 3 , R 41 , R 42 , R 43 , R 44 , R 45 , and R 51 is as defined in claim 1 .

17. A compound of the following formula, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

18. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 17 , selected from the group consisting of

19. A pharmaceutical composition, comprising the compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 , and optionally further comprising a pharmaceutically acceptable carrier.

20. A method for treating related to HBV infection, comprising administering to a patient in need thereof a therapeutically effective amount of the compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 .